Becton, Dickinson (BDX) fiscal Q3 results:
Revenues: $3,855M (-11.4%); BD Medical: $2,122M (-8.2%); BD Life Sciences: $951M (-10.1%); BD Interventional: $782M (-20.3%).
Net Income: $277M (-32.9%); EPS: $0.97 (-35.8%); non-GAAP EPS: $2.20 (-28.6%).
CF Ops: $2,058M (+5.1%).
FY 2020 Guidance: Revenues: decrease 2.5% – 3.0% percent on reported; non-GAAP EPS: $9.80 – 10.00. The average analyst estimate is $10.38.
For comparison purposes, original outlook provided during FQ1 was revenue growth of 1.5% – 2.5%; non-GAAP EPS: $11.90 – 12.10. Subsequent guidance, until today, was withdrawn due to pandemic disruptions.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.